现在，吉利德决定将这2款候选疫苗完全掌控在自己手中。根据5月22日提交给美国证券交易委员会的一份文件， 吉利德将为此总共支付1000万美元，其中300万美元将在交易结束时支付，剩余的700万美元将分三阶段支付，对应技术转移计划的推进步骤。

Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful ...

Clearway Energy, Inc. (NYSE:CWEN) is a major player in the clean energy sector, operating one of the largest renewable energy ...